Metastasis is responsible for the vast majority of cancer-related deaths. During this process, circulating tumour cells (CTCs) are generated, spread from the primary tumour, colonize distant organs and lead to overt metastatic disease. During the past decade a growing interest in CTCs has spread out across the oncology field, especially looking at their capacity as prognostic elements of cancer.
Despite important progresses in understanding and detecting CTCs, most of the assays still have low sensitivity; mainly due to the use of a few epithelial biomarkers to identify and isolate them from whole blood.
A Spanish hospital research group has designed a procedure to detect circulating tumor cells (CTCs), both circulating tumor cells of phenotype epithelial as circulating tumor cells that present Epithelial-Mesenchymal Transition (EMT) markers using miRNA-21 as a biomarker.
The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parts to use the technology.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations to adapt the technologies to biological and therapeutic applications.